![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Because drug development is not a static process, a drug’s market authorisation may change over time. In many cases, the number of indications for which a drug is approved increases. Because this facet of drug development also comes at significant costs, a corresponding patent filing strategy is required to protect these investments. The strategy as applied to rituximab, which is approved for a variety of indications, is discussed in this review.
Keywords: :
Disclosure of Potential Conflicts of Interest
The author is involved in pending oppositions against some of the patents mentioned herein.
Disclaimer
The information provided herein reflect the personal views and considerations of the author. They do not represent legal counsel and should not be attributed to Michalski • Hüttermann and Partners Patent Attorneys or to any of its clients. Patent numbers and patent lifetimes have been verified with utmost care, but no liability is taken for their correctness.